Bioinformation Therapy for Lung Cancer

• Status: Completed
• Trial end date: 2018-09-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fuda Cancer Hospital, Guangzhou
• Collaborator: Shengxin Biotechnology Institute, Beijing
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies

• Body tumor 1-6, with at least one tumor length > 2 cm

• KPS ≥ 70, lifespan > 6 months

• Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

• Patients with cardiac pacemaker

• Patients with brain metastasis

• Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction